Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study

Publication | Closed Access

DOI

Citations

References

2013

Year

Christie M. Ballantyne, Ron C. Hoogeveen, Joe L. Raya, Valerie A. Cain, Mike K. Palmer, Björn W. Karlson

Atherosclerosis

Cardiovascular DiseaseMedicineSimvastatin 40HyperlipidemiaRosuvastatin 10Lipoprotein MetabolismPharmacologyAtherosclerosisDyslipidemia